The study is observational with descriptive purposes, aimed at enhancing and deepening current knowledge and providing a foundation for future studies. Specifically, it seeks to identify predictive factors for aggressive disease progression, the development of frailty, the need for surgery and post-surgical outcomes, the development of neoplasia, the assessment of drug safety, and the quality of life in relation to medications or post-surgery.
Signed informed consent
Age > 14 years
Diagnosis of inflammatory bowel disease (Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Microscopic Colitis) according to ECCO guidelines
Having undergone at least one outpatient visit and/or hospitalization at the Regional Reference Center for IBD "Massimo Campieri"
None
The population consists of adult patients with IBD being followed at the Regional Reference Center "Massimo Campieri," which includes the General Surgery Unit and the IBD Specialties Unit of IRCCS AOUBO for the management of intestinal and extraintestinal conditions. Enrollment will take place in the IBD Specialties Unit during follow-up outpatient visits, hospital admissions, or through a phone/email invitation conducted by staff affiliated with the Unit.
Cohort
Prospective
Not listed
Percentage of patients with aggressive disease progression.
Occurrence, at least once during the natural history of the patient's disease, of one or more characteristics of aggressiveness, namely: * Immunosuppressive/biotechnology/small molecule therapy due to failure of conventional therapy or severe disease * Surgery due to failure of medical therapy or the onset of complications such as strictures or fistulas * Endoscopic recurrence of disease post-surgery * Hospitalization for severe disease or the onset of complications
Percentage of fragility patients.
Presence of one or more characteristics of frailty, namely: * Polypharmacy (defined as the need to take at least one other medication for a condition other than inflammatory bowel disease) * Short bowel syndrome post-surgery (defined as a small intestine length, measured from the duodenojejunal flexure, less than 200 cm) requiring supplemental enteral/parenteral nutrition * Osteoporosis (defined as bone mineral density - BMD - with a T-score less than -2.5) with or without pathological fractures * One or more extraintestinal manifestations (EIMs)
Percentage of patients with the development of comorbidities.
Presence or absence of other comorbidities.
Percentage of patients with extraintestinal manifestations (EIMs).
Presence or absence of extraintestinal manifestations.
Percentage of patients with an adverse drug reaction.
Occurrence of adverse drug reactions classified by: * Type of adverse drug event * Severity of the adverse event according to CTCAE 5.0
IBD-Q score
Inflammatory Bowel Disease - Questionnaire (validated questionnaire).
Percentage of gastrointestinal and non-gastrointestinal infections.
Assessment of the presence or absence of infections, including the type of infection/etiology if available, diagnosed through specific serology or culture tests.
Overall survival (OS) after the diagnosis of neoplastic/infectious disease.
Days elapsed between the date of diagnosis of neoplasia/infection and the date of death.
Click on the lead sponsor to view all of their trials.
